Catalog No.
RHG17901
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:200-1:1000, IHC: 1:200-1:1000
Target
Liver fibrinogen-related protein 1, HFREP-1, HP-041, Hepatocyte-derived fibrinogen-related protein 1, HPS, FGL1, LFIRE-1, Hepassocin, Fibrinogen-like protein 1, HFREP1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q08830
Applications
ELISA, FCM, IF, IHC
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3R73
Exploring new frontiers in LAG-3 biology and therapeutics., PMID:40514283
Research advances in FGL1/LAG3 for cancer diagnosis and treatment: From basics to clinical practice., PMID:40317138
Design of NanoBiT-Nanobody-based FGL1 biosensors for early assisted diagnosis of esophageal cancer., PMID:40138964
Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs., PMID:40101708
FGL1 facilitates rather than suppresses anticancer immunity against microsatellite instable gastric cancer., PMID:39672971
A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding., PMID:38776682
The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy., PMID:38556085
Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy., PMID:38486998
Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function., PMID:38483996
[Screening and activity analysis of nanobodies against lymphocyte activation gene-3(LAG-3)]., PMID:37980554
FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation., PMID:37938970
FGL1-LAG3 axis impairs IL-10-Producing regulatory T cells associated with Systemic lupus erythematosus disease activity., PMID:37916085
The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motif., PMID:37788323
LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors., PMID:36077354
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application., PMID:35958563
LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition., PMID:35761082
Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer., PMID:35111155
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target., PMID:34526102
A Double-Antibody Sandwich ELISA for Sensitive and Specific Detection of Swine Fibrinogen-Like Protein 1., PMID:33968077
Development of a nanobody-based immunoassay for the sensitive detection of fibrinogen-like protein 1., PMID:33633363
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3., PMID:30580966
Hepassocin regulates cell proliferation of the human hepatic cells L02 and hepatocarcinoma cells through different mechanisms., PMID:21618590
A protein chip approach for high-throughput antigen identification and characterization., PMID:17549792
Evaluation of progesterone content in saliva using magnetic particle-based immuno supported liquid membrane assay (m-ISLMA)., PMID:16473507
Genetic variations in humans associated with differences in the course of hepatitis C., PMID:15063762
Isolation and characterization of a novel liver-specific gene, hepassocin, upregulated during liver regeneration., PMID:11004478
For research use only. Not for human or drug use.
